Overview of the socio-economic consequences of heart failure
- PMID: 33708497
- PMCID: PMC7944217
- DOI: 10.21037/cdt-20-291
Overview of the socio-economic consequences of heart failure
Abstract
Heart failure (HF) is a frequent cause of morbidity and mortality worldwide. The prevalence of HF increases, and in high-income countries, 1-2% of total healthcare expenditure is spent on HF. This article gives an overview on the impact of HF on health-related quality of life (HRQoL) and the economic burden of HF. Those suffering from HF are associated with a substantial decrease of HRQoL compared to individuals with most other chronic diseases and to individuals without HF. Therapeutic approaches, which decrease risk factors and lead to an improvement of the clinical status of patients, have a positive effect on HRQoL of the patients. Hospitalization rates have been shown to be correlated with disease severity, mortality, and HRQoL. Inpatient treatments of HF patients are cost intensive and the most important component for the economic burden of HF, responsible for at least half of direct cost. Prevention strategies, diagnostic and therapeutic approaches should focus on avoiding need for hospitalizations, and in particular, readmissions. Outpatient care including medication represents the second largest cost component. The cost of HF varies from less than 1,000 USD per patient in low-income countries to between 5,000 and 15,000 EUR in Europe, and between 17,000 and 30,000 USD in the US. There is a lack of study results on indirect costs. All study results on the socio-economic burden of HF clearly underscore the public health relevance of HF, showing a large economic burden for healthcare systems all over the world and a considerable impact on patients' HRQoL. The results on HRQoL are relatively homogeneous, but there are large differences across countries in respect of the economic burden they have to bear. Despite the large number of studies on the socio-economic consequences of HF further research is necessary, especially on indirect cost and for low- and middle-income countries. Future studies would benefit from a greater standardization of methods and presentation of results.
Keywords: Heart failure (HF); cost of illness; health-related quality of life (HRQoL); socio-economic burden.
2021 Cardiovascular Diagnosis and Therapy. All rights reserved.
Conflict of interest statement
Conflicts of Interest: The author has completed the ICMJE uniform disclosure form (available at http://dx.doi.org/10.21037/cdt-20-291). The series “Heart Failure in the Young and Old: Insights into Various Therapies” was commissioned by the editorial office without any funding or sponsorship. The author has no other conflicts of interest to declare.
Similar articles
-
Prevalence and socio-economic burden of heart failure in an aging society of South Korea.BMC Cardiovasc Disord. 2016 Nov 10;16(1):215. doi: 10.1186/s12872-016-0404-2. BMC Cardiovasc Disord. 2016. PMID: 27832754 Free PMC article.
-
A Remote Medication Monitoring System for Chronic Heart Failure Patients to Reduce Readmissions: A Two-Arm Randomized Pilot Study.J Med Internet Res. 2016 Apr 17;18(5):e91. doi: 10.2196/jmir.5256. J Med Internet Res. 2016. PMID: 27154462 Free PMC article. Clinical Trial.
-
Financial burden of heart failure in Malaysia: A perspective from the public healthcare system.PLoS One. 2023 Jul 5;18(7):e0288035. doi: 10.1371/journal.pone.0288035. eCollection 2023. PLoS One. 2023. PMID: 37406003 Free PMC article.
-
The annual global economic burden of heart failure.Int J Cardiol. 2014 Feb 15;171(3):368-76. doi: 10.1016/j.ijcard.2013.12.028. Epub 2013 Dec 22. Int J Cardiol. 2014. PMID: 24398230 Review.
-
The economic burden of Chagas disease: A systematic review.PLoS Negl Trop Dis. 2023 Nov 22;17(11):e0011757. doi: 10.1371/journal.pntd.0011757. eCollection 2023 Nov. PLoS Negl Trop Dis. 2023. PMID: 37992061 Free PMC article.
Cited by
-
Knee osteoarthritis: disease burden, available treatments, and emerging options.Ther Adv Musculoskelet Dis. 2024 Sep 15;16:1759720X241273009. doi: 10.1177/1759720X241273009. eCollection 2024. Ther Adv Musculoskelet Dis. 2024. PMID: 39290780 Free PMC article. Review.
-
Volenrelaxin (LY3540378) increases renal plasma flow: a randomized Phase 1 trial.Nephrol Dial Transplant. 2024 Dec 20;40(1):109-122. doi: 10.1093/ndt/gfae112. Nephrol Dial Transplant. 2024. PMID: 38782726 Free PMC article. Clinical Trial.
-
Cardiovascular events, mortality, early retirement and costs in >50 000 persons with chronic heart failure in Sweden.ESC Heart Fail. 2024 Feb;11(1):54-64. doi: 10.1002/ehf2.14480. Epub 2023 Oct 9. ESC Heart Fail. 2024. PMID: 37814495 Free PMC article.
-
Utilization and dose optimization of beta-blockers in chronic heart failure therapy: a mixed-methods study.BMC Cardiovasc Disord. 2025 Jun 8;25(1):440. doi: 10.1186/s12872-025-04901-7. BMC Cardiovasc Disord. 2025. PMID: 40484949 Free PMC article.
-
Vericiguat: The Fifth Harmony of Heart Failure with Reduced Ejection Fraction.J Cardiovasc Dev Dis. 2023 Sep 8;10(9):388. doi: 10.3390/jcdd10090388. J Cardiovasc Dev Dis. 2023. PMID: 37754817 Free PMC article. Review.
References
-
- GBD 2017 DALYs and HALE Collaborators. Global, regional, and national disability-adjusted life-years (DALYs) for 359 diseases and injuries and healthy life expectancy (HALE) for 195 countries and territories, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet 2018;392:1859-922. 10.1016/S0140-6736(18)32335-3 - DOI - PMC - PubMed
-
- Ponikowski P, Voors AA, Anker SD, et al. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). Eur J Heart Fail 2016;18:891-975. 10.1002/ejhf.592 - DOI - PubMed
Publication types
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials
Miscellaneous